NYSE / NASDAQ · SEC EDGAR
Equity research
Start with company fundamentals. Compare growth and capital returns, then narrow the research to the companies that meet your criteria.
Research preview · Quarterly financial statements · No price quotes · Not financial advice
Example screens
- Best combined rank669Issuers with both EPS acceleration and ROE, highest rank first.
- Profitable growth142ROE at least 15% and revenue growth at least 10%.
- Earnings acceleration841EPS acceleration at or above zero, largest first.
- High return on equity378ROE at least 25%, highest first.
- NYSE only364The same ranking with NYSE listings only.
| Company | Combined rank | EPS acceleration | Revenue growth | ROE | Net margin | Reporting period |
|---|---|---|---|---|---|---|
| ATPCAgape ATP CorpNASDAQ | — | — | -93.4% | -5.2% | -109.3% | 2026-06-30Filed 2026-08-14 |
| ATRAAtara Biotherapeutics, Inc.NASDAQ | — | -160.1 pp | -96.4% | — | -269.4% | 2026-06-30Filed 2026-08-12 |
| ATRCAtriCure, Inc.NASDAQ | — | — | 12.8% | 2.0% | 1.9% | 2026-06-30Filed 2026-07-27 |
| ATTOAttovia Therapeutics, Inc.NASDAQ | — | — | — | — | — | 2026-06-30Filed 2026-09-02 |
| ATXGADDENTAX GROUP CORP.NASDAQ | — | — | 316.0% | -6.6% | -21.1% | 2026-06-30Filed 2026-08-14 |
| ATYRaTYR PHARMA INCNASDAQ | — | — | — | -124.6% | — | 2026-06-30Filed 2026-08-07 |
| AUBNAUBURN NATIONAL BANCORPORATION, INCNASDAQ | — | -16.3 pp | — | — | — | 2026-06-30Filed 2026-08-11 |
| AUIDauthID Inc.NASDAQ | — | — | -66.0% | -902.3% | -1450.5% | 2026-06-30Filed 2026-08-14 |
| AURAurora Innovation, Inc.NASDAQ | — | — | 200.0% | -51.9% | -13328.6% | 2026-09-30Filed 2026-10-28 |
| AURAAura Biosciences, Inc.NASDAQ | — | — | — | -41.6% | — | 2026-06-30Filed 2026-08-11 |
| AUTLAutolus Therapeutics plcNASDAQ | — | — | 118.4% | -374.3% | -238.7% | 2026-06-30Filed 2026-08-11 |
| AUUDAUDDIA INC.NASDAQ | — | — | — | -90.1% | -126962.0% | 2026-06-30Filed 2026-08-14 |
| AVATAvalanche Treasury CorpNASDAQ | — | — | — | — | — | 2026-06-30Filed 2026-08-19 |
| AVAVAeroVironment IncNASDAQ | — | — | 5.7% | — | — | 2026-08-01Filed 2026-09-10 |
| AVBCAvidia Bancorp, Inc.NYSE | — | — | — | 4.5% | — | 2026-06-30Filed 2026-08-13 |
| AVBPArriVent BioPharma, Inc.NASDAQ | — | — | — | -44.6% | — | 2026-06-30Filed 2026-08-12 |
| AVDAMERICAN VANGUARD CORPNYSE | — | — | -9.7% | -30.1% | -10.7% | 2026-06-30Filed 2026-09-30 |
| AVEXAEVEX Corp.NYSE | — | — | 99.5% | — | — | 2026-06-30Filed 2026-08-12 |
| AVGOBroadcom Inc.NASDAQ | — | 129.9 pp | 85.5% | — | — | 2026-08-02Filed 2026-09-10 |
| AVIRAtea Pharmaceuticals, Inc.NASDAQ | — | — | — | -81.0% | — | 2026-06-30Filed 2026-08-12 |
| AVLNAvalyn Pharma Inc.NASDAQ | — | — | — | — | — | 2026-06-30Filed 2026-08-12 |
| AVNTAVIENT CORPNYSE | — | — | 5.8% | 7.0% | 5.1% | 2026-06-30Filed 2026-08-06 |
| AVNWAVIAT NETWORKS, INC.NASDAQ | — | — | — | 0.9% | — | 2026-07-03Filed 2026-08-27 |
| AVRAnteris Technologies Global Corp.NASDAQ | — | — | 63.3% | -41.2% | -4619.3% | 2026-06-30Filed 2026-08-11 |
| AVTAVNET INCNASDAQ | — | — | 47.7% | 6.7% | 1.2% | 2026-06-27Filed 2026-08-14 |
How the lists overlap
EPS acceleration is the change in year-over-year quarterly EPS growth, expressed in percentage points. Revenue growth compares matching quarters a year apart. ROE divides four consecutive quarters of net income by equity at the same latest reporting date.
The combined rank averages the EPS acceleration and ROE percentiles among issuers with both metrics. It ranges from 0 to 100 and describes relative position within this covered group. It is not a probability or a performance estimate.
Net margin uses four consecutive quarters with matching revenue and net income. Missing quarters stay unavailable; additive fourth-quarter values may be derived from annual minus nine-month totals known at the filing date. EPS is never derived this way.
What this data covers
Source: SEC EDGAR company facts. Each value must have been filed on or before the displayed as-of date. Reporting periods older than 185 days are excluded.
The current exchange universe includes multiple security types. The screen shows one ticker per issuer with supported US-GAAP facts; it is not a complete historical stock universe. Missing companies and ratios are coverage gaps, not negative assessments.
Snapshots update daily. Close-price series are shown for the companies the BibaMoney price store covers — the coverage line above states how many of the current matches that is, and a card without a series says so instead of drawing a line. Sector metadata and validated price outcomes are not included: no price outcome in this screen has been checked out of sample.
Macro context: the 10Y–3M Treasury curve was non-inverted on 2026-11-06. Source: FRED / Federal Reserve.